Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

NRIX
Nurix Therapeutics, Inc. Common stock
stock NASDAQ

At Close
Jul 2, 2026 3:59:57 PM EDT
23.98USD+0.293%(+0.07)1,427,663
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 2, 2026 9:01:30 AM EDT
23.92USD+0.042%(+0.01)659
After-hours
Jul 2, 2026 4:05:30 PM EDT
23.60USD-1.585%(-0.38)178,393
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
08:21AM EST  The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron   Benzinga
Jan 27, 2022
05:42PM EST  Nurix Therapeutics: Q4 Earnings Insights   Benzinga
04:11PM EST  Nurix Therapeutics Q4 EPS $(0.85) Down From $(0.51) YoY, Sales $7.40M Up From $6.69M YoY   Benzinga
Jan 10, 2022
07:00AM EST  Nurix leads protein modulation field with four active clinical stage programs   GlobeNewswire Inc
Jan 3, 2022
04:35PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences, Sotera Health, Eagle Pharma   Benzinga
04:12PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences   Benzinga
04:03PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights   Benzinga
04:01PM EST  Nurix Therapeutics to Present at 40th Annual J.P. Morgan   GlobeNewswire Inc
Dec 29, 2021
06:08AM EST  HC Wainwright & Co. Initiates Coverage On Nurix Therapeutics with Buy Rating, Announces Price Target of $62   Benzinga
Dec 12, 2021
09:32AM EST  Nurix Therapeutics Announced UK Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presented New Preclinical Data at ASH 2021; Said Anticipates Dosing First Patient in H1 2022   Benzinga
09:00AM EST  U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022   GlobeNewswire Inc
Nov 12, 2021
07:15AM EST  Nurix Therapeutics Reports Clearance Of Investigational New Drug Application For DeTIL-0255 For Variety Of Solid Tumors   Benzinga
07:09AM EST  Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial   GlobeNewswire Inc
07:07AM EST  DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL   GlobeNewswire Inc
Nov 9, 2021
04:01PM EST  Nurix Therapeutics, Inc.(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat Arthur T. Sands, M.D., Ph.D., Nurixs president and chief executive officer, will participate in fireside chats at the following conferences in November:   GlobeNewswire Inc
Oct 27, 2021
12:22PM EDT  SVB Leerink Maintains Outperform on Nurix Therapeutics, Raises Price Target to $64   Benzinga
11:06AM EDT  Shares of Nurix Therapeutics, Inc. (NRIX) are gaining nearly 14% on Wednesday morning after the company announced initial data from the first Phase 1a dose escalation trial of its lead drug candidate NX-2127 in patients with relapsed or refractory B-cell malignancies.   RTTNews
07:38AM EDT  Nurix Therapeutics Presents Initial Data From First Phase 1a Dose Escalation Trial Of NX-2127 In Patients With Relapsed Or Refractory B Cell Malignancies   Benzinga
07:00AM EDT  Robust BTK target degradation achieved in all patients treated to date   GlobeNewswire Inc
Oct 26, 2021
04:40PM EDT  Nurix Therapeutics Will Present Initial Target Degradation Data From First Phase 1 Trial Of NX-2127 In B Cell Malignancies At Targeted Protein Degradation Summit Wednesday, Oct. 27, 2021 At 11:45 a.m. EDT, Will Host Call At 8:30 a.m.   Benzinga
04:02PM EDT  Presentation to include initial pharmacokinetic and BTK degradation data   GlobeNewswire Inc
Oct 21, 2021
07:00AM EDT  Nurix Therapeutics to Participate in the 4th Annual Targeted   GlobeNewswire Inc
Oct 15, 2021
10:59AM EDT  UPDATE: SVB Leerink On Nurix Outperform Reiteration: Firm Notes Co. Has 'Started Dose Escalation Portion Of NX-1607 Phase 1A/B Study Design' & Sees Phase 1 Trial Initiation For DeTIL-0255 Possible Within FY21; Believes De-Risking NX-1607 Helpful To Thesis   Benzinga
10:59AM EDT  SVB Leerink Reiterates Outperform Rating On Nurix Therapeutics, Inc. With $50 Price Target   Benzinga
Oct 14, 2021
04:03PM EDT  Nurix Therapeutics Q3 EPS $(0.65) Down From $(0.59) YoY, Sales $10.25M Up From $4.08M YoY   Benzinga
04:02PM EDT  Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer   GlobeNewswire Inc
11:18AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021   Benzinga
07:37AM EDT  SVB Leerink Initiates Coverage On Nurix Therapeutics with Outperform Rating, Announces Price Target of $50   Benzinga
Sep 30, 2021
07:00AM EDT  Nurix Therapeutics Expands its Board of Directors with the   GlobeNewswire Inc
Jul 29, 2021
02:25PM EDT  Return on Capital Employed Insights for Nurix Therapeutics   Benzinga
Jul 13, 2021
04:06PM EDT  Nurix Therapeutics Q2 EPS $(0.60), Sales $7.09M Up From $4.18M YoY   Benzinga
04:03PM EDT  Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies   GlobeNewswire Inc
Jun 21, 2021
04:02PM EDT  Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development   Benzinga
04:01PM EDT  Nurix Therapeutics Announces Appointment of Stefani A. Wolff as   GlobeNewswire Inc
Jun 2, 2021
07:00AM EDT  Orally available NX-5948 is a potent selective degrader of Brutons Tyrosine Kinase (BTK) without IMiD activity   GlobeNewswire Inc
Jun 1, 2021
04:00PM EDT  Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc. (formerly Seattle Genetics, Inc.) and serves as its president, chief executive officer, and chairman of the board.   GlobeNewswire Inc
May 21, 2021
07:00AM EDT  Nurix Therapeutics Announces Upcoming Presentation of NX-5948   GlobeNewswire Inc
May 11, 2021
07:00AM EDT  Nurix Therapeutics, Inc.(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat members of Nurix management team will participate in the following conferences in May:   GlobeNewswire Inc
Apr 30, 2021
12:21PM EDT  RBC Capital Initiates Coverage On Nurix Therapeutics with Outperform Rating, Announces Price Target of $42   Benzinga
07:26AM EDT  CORRECTION: RBC Capital Maintains Outperform on Nurix Therapeutics, Announces $42 Price Target - Correct Rating Action is Initiates   Benzinga
07:21AM EDT  RBC Capital Maintains Outperform on Nurix Therapeutics, Announces $42 Price Target   Benzinga
Apr 14, 2021
02:37PM EDT  Mid-Afternoon Market Update: Dow Gains Over 100 Points; Bed Bath & Beyond Shares Plummet   Benzinga
01:20PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021   Benzinga
12:20PM EDT  Mid-Day Market Update: Crude Oil Rises 4.5%; Grupo Televisa Shares Spike Higher   Benzinga
08:57AM EDT  Berenberg Initiates Coverage On Nurix Therapeutics with Buy Rating   Benzinga
Apr 13, 2021
04:03PM EDT  Nurix Therapeutics Q1 EPS $(0.63)   Benzinga
04:01PM EDT  On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021   GlobeNewswire Inc
Apr 7, 2021
07:00AM EDT  Nurix Therapeutics, Inc.(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat Arthur T. Sands, M.D., Ph.D., Nurixs chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14th, 2021 at 11:45 a.m. ET.   GlobeNewswire Inc
Mar 16, 2021
09:53AM EDT  Nurix Announces Collaboration For The Discovery Of Novel Drugs To Treat Pediatric Cancers   RTTNews
09:32AM EDT  Nurix Therapeutics Reports Collaboration For Discovery Of Novel Drugs To Treat Pediatric Cancers   Benzinga
09:31AM EDT  Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastomaProgram is one of four in Alexs Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative   GlobeNewswire Inc
Mar 10, 2021
05:14PM EST  Nurix Therapeutics Announces The Presentation Of NX-1607 Preclinical Data At The AACR   Benzinga
05:12PM EST  CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cellsPreclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade   GlobeNewswire Inc
Mar 9, 2021
04:01PM EST  Nurix Therapeutics Announces Closing of Public Offering of Common   GlobeNewswire Inc
07:30AM EST  Nurix Therapeutics, Inc.(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat Arthur Sands, M.D., Ph.D., Nurixs chief executive officer, will participate and present at the following conferences in March:   GlobeNewswire Inc
Mar 4, 2021
09:09PM EST  Nurix Therapeutics Prices Public Offering Of 4.50 Mln Shares At $31.00/shr   RTTNews
08:01PM EST  Nurix Therapeutics Announces Pricing of Upsized Public Offering of   GlobeNewswire Inc
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
Mar 2, 2021
04:21PM EST  Nurix Therapeutics Announces 4M Share Common Stock Offering   Benzinga
04:16PM EST  Nurix Therapeutics Announces Launch of Proposed Public Offering of   GlobeNewswire Inc
Feb 16, 2021
04:08PM EST  Nurix Therapeutics Q4 EPS $(0.51) Up From $(3.55) YoY   Benzinga
04:01PM EST  First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies   GlobeNewswire Inc
Jan 29, 2021
11:47AM EST  JP Morgan Maintains Overweight on Nurix Therapeutics, Raises Price Target to $56   Benzinga
Jan 19, 2021
11:16PM EST  The lockup period of San Francisco, California-based Nurix Therapeutics (NRIX) expires tomorrow , i.e., January 20, 2021.   RTTNews
Jan 8, 2021
09:31AM EST  Needham Maintains Buy on Nurix Therapeutics, Raises Price Target to $44   Benzinga
Jan 7, 2021
07:29AM EST  Biopharmaceutical company Nurix Therapeutics, Inc. (NRIX) said Thursday it has expanded its global strategic collaboration with French drug maker Sanofi (SNYNF, SNY) to discover, develop and commercialize innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas.   RTTNews
07:12AM EST  Nurix Therapeutics Announces Expansion Of Collaboration With Sanofi To Develop Novel Targeted Protein Degradation Therapies; With Expansion, Nurix Receives $22M Payment   Benzinga
07:04AM EST  Nurix Therapeutics Announces Expansion Of Its Global Strategic Collaboration With Sanofi   RTTNews
07:00AM EST  Nurix Therapeutics Announces Expansion of its Strategic   GlobeNewswire Inc
Jan 5, 2021
07:00AM EST  Nurix Therapeutics, Inc.(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat Arthur Sands, M.D., Ph.D., Nurixs chief executive officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:40 p.m. EST.   GlobeNewswire Inc
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
10:08AM EST  Nurix Therapeutics Presents Preclinical Data At ASH   Benzinga
10:01AM EST  Nurix Therapeutics Presents Preclinical Data at 62nd American   GlobeNewswire Inc
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 25, 2020
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 19, 2020
09:41AM EST  Benzinga's Top Upgrades, Downgrades For November 19, 2020   Benzinga
06:07AM EST  Baird Initiates Coverage On Nurix Therapeutics with Outperform Rating, Announces Price Target of $40   Benzinga
Nov 9, 2020
07:00AM EST  Nurix Therapeutics, Inc.(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat it will be presenting at the following healthcare investor conferences:   GlobeNewswire Inc
Nov 4, 2020
04:14PM EST  Nurix Therapeutics to Present Preclinical Data At Upcoming 5th Medicinal Chemistry & Protein Degradation Summit Nov. 16 And 62nd American Society of Hematology Annual Meeting And Exposition Dec. 7   Benzinga
04:01PM EST  Nurix Therapeutics to Present Preclinical Data at Upcoming 5th   GlobeNewswire Inc
Oct 26, 2020
08:00AM EDT  Nurix Therapeutics Announces Appointment of Robert Tjian as   GlobeNewswire Inc
Oct 14, 2020
04:12PM EDT  Nurix Therapeutics Q3 Loss/share $0.59 Vs. Loss $0.66 Year Ago   RTTNews
04:08PM EDT  Nurix Therapeutics Q3 EPS $(0.59) Misses $(0.41) Estimate, Sales $4.08M Miss $6.34M Estimate   Benzinga
04:05PM EDT  Completed recent IPO raising approximately $238.5 million in gross proceeds   GlobeNewswire Inc
Oct 6, 2020
08:00AM EDT  Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.   GlobeNewswire Inc
Aug 18, 2020
11:13AM EDT  Nurix Therapeutics shares are trading higher after multiple firms initiated coverage on the stock with a bullish rating. UPDATE: Shares have since reversed, now lower.   Benzinga
09:48AM EDT  Benzinga's Top Upgrades, Downgrades For August 18, 2020   Benzinga
08:20AM EDT  Needham Initiates Coverage On Nurix Therapeutics with Buy Rating, Announces Price Target of $35   Benzinga
06:59AM EDT  Stifel Initiates Coverage On Nurix Therapeutics with Buy Rating, Announces Price Target of $34   Benzinga
05:36AM EDT  JP Morgan Initiates Coverage On Nurix Therapeutics with Overweight Rating, Announces Price Target of $35   Benzinga
05:19AM EDT  Piper Sandler Initiates Coverage On Nurix Therapeutics with Overweight Rating, Announces Price Target of $40   Benzinga
Aug 14, 2020
08:26AM EDT  The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal   Benzinga
Jul 24, 2020
12:59PM EDT  Nurix Therapeutics Shares Open For Trade At $18.06; IPO Priced At $19/Share   Benzinga
11:22AM EDT  Nurix Therapeutics IPO Opened For Quote At 11 a.m. EDT, Was Expected To Open For Trade After 11:10 a.m.; Still Waiting On Opening Print; IPO Priced At $19   Benzinga
Jul 23, 2020
08:24PM EDT  Nurix Therapeutics Prices 11M Share IPO @$19/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC